The most common adverse reactions in the Phase III trial were gastrointestinal, reported by 27 (93%) of 29 patients.
FORBES: FDA Approves Lomitapide For Homozygous Familial Hypercholesterolemia
应用推荐
模块上移
模块下移
不移动